Evolving development of PD-1 therapy: Cetrelimab (JNJ-63723283) from monotherapy to combination with erdafitinib.

Victor  Moreno

Employment - START

Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Janssen Oncology; Merck

Speakers' Bureau - Bayer

Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); E-therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Menarini (Inst); Merck (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)

Expert Testimony - Medscape/Bayer; Nanobiotix

Travel, Accommodations, Expenses - Sanofi/Regeneron

Other Relationship - Bristol-Myers Squibb

Yohann  Loriot

Honoraria - Pfizer; Sanofi

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Janssen; Janssen (Inst); MSD Oncology; MSD Oncology (Inst); Roche; Seagen

Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); CureVac (Inst); Exelixis (Inst); Incyte (Inst); Janssen Oncology (Inst); Medivation (Inst); MSD Oncology (Inst); Nektar (Inst); Oncogenex (Inst); Pfizer (Inst); Sanofi (Inst)

Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen

Piotr  Rutkowski

Honoraria - Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche

Consulting or Advisory Role - Amgen; Blueprint Medicines; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre

Speakers' Bureau - Lilly; Novartis; Pfizer

Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Roche (Inst)

Travel, Accommodations, Expenses - Orphan Europe; Pierre Fabre

Carmen  Beato

No Relationships to Disclose

Enriqueta  Felip

Consulting or Advisory Role - Abbvie; AstraZeneca; BerGenBio; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Janssen; Lilly; Medscape; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; priME Oncology; Roche; Samsung; Takeda; touchIME

Speakers' Bureau - AbbVie; Abbvie; AstraZeneca; BerGenBio; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Janssen; Lilly; medscape; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; Prime Oncology; Roche; Samsung; Takeda; touchIME

Research Funding - EMD Serono (Inst); Merck (Inst)

Other Relationship - GRÍFOLS

Ignacio  Duran

Honoraria - Astellas Pharma; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Janssen Oncology; MSD Oncology; Roche/Genentech

Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Janssen Oncology; MSD Oncology; Novartis; Pharmacyclics; Roche/Genentech; Seagen

Research Funding - Astellas Pharma (Inst); AstraZeneca Spain (Inst); Janssen Oncology (Inst); Roche/Genentech (Inst)

Travel, Accommodations, Expenses - AstraZeneca Spain; Ipsen; Roche/Genentech

Dariusz  Kowalski

Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Pfizer; Roche/Genentech; Takeda

Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Pfizer; Roche/Genentech; Takeda

Salvatore  Siena

Stock and Other Ownership Interests  - Guardant Health; Myriad Genetics

Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; CheckmAb; Clovis Oncology; Daiichi Sankyo; Incyte; Merck; Novartis; Roche/Genentech; Seagen

Research Funding - MSD Oncology (Inst)

Patents, Royalties, Other Intellectual Property - Amgen

Travel, Accommodations, Expenses - Amgen; Bayer; Roche

Diego  Cortinovis

No Relationships to Disclose

Lionnel  Geoffrois

Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; MSD Oncology

Travel, Accommodations, Expenses - Ipsen; Janssen Oncology; Merck KGaA; MSD Oncology

Elizabeth Ruth  Plummer

Honoraria - Amgen (I); AstraZeneca/MedImmune; Bristol-Myers Squibb; Novartis Pharmaceuticals UK Ltd.; Pfizer (I); Tesaro

Consulting or Advisory Role - Astex Pharmaceuticals; Bayer; Biosceptre; Clovis Oncology; CV6 Therapeutics; Cybrexa Therapeutics; Ellipses Pharma; Karus Therapeutics; Novartis; Octimet; Pierre Fabre; Sanofi/Aventis

Research Funding - AstraZeneca/MedImmune (Inst)

Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)

Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology

Scott T.  Tagawa

Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Bayer; Clovis Oncology; Dendreon; Endocyte; Genentech; Genomic Health; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Sanofi; Tolmar

Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)

Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi

(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics; Telix Pharmaceuticals

Emiliano  Calvo

Employment - HM Hospitales; START

Leadership - START

Stock and Other Ownership Interests  - International Cancer Consultants; Oncoart Associated; START

Honoraria - HM Hospitales

Consulting or Advisory Role - Abbvie; Amcure; AstraZeneca; Celgene; EUSA Pharma; Gerson Lehrman Group; Guidepoint Global; Janssen-Cilag; Nanobiotix; Novartis; Pfizer; PsiOxus Therapeutics; Roche/Genentech; Seagen; SERVIER

Speakers' Bureau - Novartis

Research Funding - AstraZeneca; BeiGene; Novartis; START

Travel, Accommodations, Expenses - Roche/Genentech

Other Relationship - Investigational Therapeutics in Oncological Sciences

Begona  Mellado

Consulting or Advisory Role - Amgen (I); Astellas Oncology; AstraZeneca; Bayer; Janssen; Pfizer; Pfizer (I); Roche; Roche (I)

Research Funding - Amgen; Pfizer; Roche

Anne  OHagan

Employment - Janssen Research & Development

Stock and Other Ownership Interests  - Janssen Research & Development

Sydney  Akapame

Employment - Janssen Research & Development

Manish  Monga

Employment - Janssen Research & Development

Stock and Other Ownership Interests  - Janssen Research & Development

James  Greger

Employment - Janssen Research & Development

Stock and Other Ownership Interests  - GlaxoSmithKline; Johnson & Johnson

Patents, Royalties, Other Intellectual Property - Janssen Research & Development

Nebedita  Bandyopadhyay

Employment - Janssen Research & Development

Stock and Other Ownership Interests  - Janssen Research & Development

Arlene O.  Siefker-Radtke

Consulting or Advisory Role - AstraZeneca; Bavarian Nordic; BioClin Therapeutics; Bristol-Myers Squibb; EMD Serono; Genentech; Inovio Pharmaceuticals; Janssen; Merck; NCCN; Nektar; Seagen

Research Funding - BioClin Therapeutics; Bristol-Myers Squibb; Janssen; Merck Sharp & Dohme; Michael and Sherry Sutton Fund for Urothelial Cancer; Nektar; NIH; Takeda

Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.